Skip to main content
. 2022 Apr 17;11(20):3743–3750. doi: 10.1002/cam4.4750

TABLE 1.

Baseline characteristics

All, n (%) Preexisting ILS p
Yes, n (%) No, n (%)
Patients 195 40 155
Age
Median (range) 73 (44–95) 77 (46–88) 72 (44–95) 0.0043
≥75 years 87 (45) 26 (65) 61 (39)
Sex 0.59
Male 71 (36) 16 (40) 55 (35)
ECOG PS 0.27
0–1 158 (81) 30 (75) 128 (83)
≥2 37 (19) 10 (25) 27 (17)
Smoking status 0.28
Never‐smoker 117 (60) 21 (53) 96 (62)
Current or former smoker 78 (40) 19 (47) 59 (38)
EGFR mutation type
Major mutation 78 (40) 11 (28) 67 (43)
Major + T790M 113 (58) 27 (68) 86 (55)
Other 4 (2.1) 2 (5) 2 (1.3)
EGFR‐TKI 0.15
Naïve 80 (41) 12 (30) 68 (44)
Treated 115 (59) 28 (70) 87 (56)
Thoracic radiotherapy 6 (3.1) 4 (10) 2 (1.3) 0.017
Previous treatment with ICIs 1 (0.51) 0 (0.0) 1 (0.65)
Preexisting ILS
Indeterminant ILA 19 (48)
ILA 21 (53)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group; performance status; EGFR, epidermal growth factor receptor: major mutation, exon 19 deletion and L858R mutation; ICIs, immune checkpoint inhibitor; ILA, interstitial lung abnormalities; ILS, interstitial lung abnormal shadow; TKI, tyrosine kinase inhibitor.